Longeveron Inc (LGVN) — Titan Protect Analysis

LGVN

Longeveron Inc

Healthcare · ·

$0.73

Data: 2026-06-03

✓ ETHICAL PASS

NONE MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$24M

Total market value of the company

Trailing P/E

N/A

Forward P/E

-0.50

Based on estimated future earnings — lower means cheaper

Rev Growth

+4.5%

Year-over-year revenue change

Profit Margin

N/A

How much profit the company keeps from each dollar of revenue

ROE

-135.2%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$8.00

+996% from current price — median analyst estimate

Recommendation

NONE

Consensus view from 3 analysts covering this stock

About Longeveron Inc

Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States. Its lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors which is in phase 3 clinical trial to treat hypoplastic left heart syndrome; completed phase 2a clinical trial to treat Alzheimer's disease, as well as in phase 2b clinical trial to

https://longeveron.com

Country: United States Employees: 38 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

DISTRIBUTION

Smart money appears to be selling into strength — caution

Sharpe Ratio

0.493

Positive but modest risk-adjusted returns

Kelly Fraction

0.0219

Modest edge detected — smaller position warranted

Calmar Ratio

-0.161

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-14.4%

Historical annualised return based on price data

Max Drawdown

-89.4%

Largest peak-to-trough decline — the worst it has been

HMM State

BEAR

Statistical model detects bearish conditions

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

N/A

52W High

$1.80

59% below the year high

52W Low

$0.48

54% above the year low

Avg Volume

5,499,211

Average daily shares traded — higher means easier to buy and sell

Short Ratio

4.6

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-1.14

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

4.67

Heavy leverage — higher financial risk if revenues decline

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

65.1%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-1,199.8%

Profit from core operations before interest and tax

Free Cash Flow

$-10,616,625

Negative — the business is spending more than it generates

Revenue (TTM)

$1M

Total revenue over the last 12 months

Net Income

$-22,429,000

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$10.45

Target Median

$8.00

Target Low

$3.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go